Pair Name	Lentinan, Oxaliplatin
Partner Name	Oxaliplatin
Disease Info	[ICD-11: 2B70]	Esophageal cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CALR	hsa811
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Expression	HSP90AA1	hsa3320
	Up-regulation	Expression	HSPA1A	hsa3303
In Vitro Model	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens (Human)	CVCL_6898
Result	These data imply that LNT increases the susceptibility of esophageal cancerous cells to Oxa by driving EC-109 cells to display immunogenic death. Therefore, LNT combined with Oxa may be an effective method in esophageal cancer management.

Pair Name	Lentinan, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Result	The current evidence prompted that Lentinan combined with cisplatin in thoracic injection might benefit patients with NSCLC on a certain extent; this systematic review revealed some definite conclusions about the application of Lentinan combined with cisplatin in thoracic injection for NSCLC. Due to the low methodological quality, high risk of bias, and inadequate reporting on clinical data, these results still require verification by a large number of well designed, heterogeneous RCT studies. More rigorous, multicenter, sufficient-sample, and double-blind RCTs are warranted.